NASDAQ · PHARMACEUTICAL PREPARATIONS · MID CAP
AC Immune SA ACIU
11 fiscal years on record · CHF · FY2025 reported · SEC filings only
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Growth
CHF 3.6M
Revenue, FY2025 · full 11-year series below
Revenue CHF M
Net income CHF M
FY2025 · Revenue 3.6 · Net income -70.4
50M100M-30M-60M
20152018202120242025
Compound annual growth
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
·
Operating margin
Net margin
FY2025 · Operating -1940.1% · Net ·
-500%-1000%-1500%
201520202025
ROE
FY2025 · ROE -89.7%
10%20%-50%
201520202025
Three returns, three denominators.
Each CHF of equity lost 90 cents this year.
The 11-year record
11 fiscal years
Every figure from documents filed with the SEC · CHF
row low → row highnegative—not applicable◌not available in our data
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue CHF B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 |
| Operating income CHF B | −0.1 | −0.1 | −0.1 | −0.1 | −0.1 | −0.1 | 0.0 | −0.0 | −0.0 | −0.0 | 0.0 |
| EBITDA CHF B | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ |
| Income tax CHF B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Net income CHF B | −0.1 | −0.1 | −0.1 | −0.1 | −0.1 | −0.1 | 0.0 | −0.1 | −0.0 | −0.0 | 0.0 |
| Free cash flow CHF B | −0.1 | 0.1 | −0.1 | −0.1 | −0.1 | −0.1 | 0.1 | −0.0 | −0.0 | −0.0 | 0.0 |
| EPS, diluted CHF | −0.70 | −0.51 | −0.64 | −0.85 | −0.97 | −0.86 | 0.64 | −0.82 | −0.46 | −0.14 | 0.44 |
| Dividend / sh CHF | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ |
| Payout % — not applicable: no dividend | — | — | — | — | — | — | — | — | — | — | — |
| ROE % | −89.7 | −37.3 | −32.9 | −35.3 | −32.6 | −25.4 | 20.2 | −34.6 | −20.4 | −6.6 | 28.5 |
Slide the table for earlier years. "—" not applicable · "◌" not available in our data.
Provenance
Company facts, as filed
How we verify · 0 failures in 42 reconciliationsAUDITED
Reconciled in 11 of the 11 fiscal years we could check. 18 checks were skipped: the balance sheet is not tagged before 2016. Eight checks were skipped: EPS is not tagged before 2015.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inoutside the United States — SEC code V8
Fiscal year endsDecember 31
Data on record since2015